Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Nicolò Pecorelli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0883-8196; OpenAlex author ID A5013479134. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 3 papers · 2025: 3 papers · 2026: 6 papers

Papers 21

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Pancreatic adenocarcinoma nutritional-clinical index (PANCIN): A novel prognostic tool in advanced pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.02.015↗
  3. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Co-author DOI 10.1016/j.eclinm.2026.104190↗
  4. Multimodal Prehabilitation In Pancreatic cancer Patients undergoing surgery (PIPS): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-026-09467-z↗
  5. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  6. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  7. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  8. Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological a… Co-author DOI 10.1093/bjsopen/zraf033↗
  9. Prognostic Validation of Perineural Invasion Severity Score in Pancreatic Cancer: A Prospective Study. Co-author DOI 10.1097/sla.0000000000006920↗
  10. Prognostic value of preoperative CT scan derived body composition measures in resected pancreatic cancer. First author DOI 10.1016/j.ejso.2023.02.005↗
  11. Communication, understanding and engagement of patients with pancreatic cancer at time of diagnosis. Co-author DOI 10.1016/j.pan.2024.02.008↗
  12. Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition". Co-author DOI 10.1245/s10434-024-15105-2↗
  13. Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant treatment. Co-author DOI 10.1016/j.ejso.2022.12.006↗
  14. Pancreatectomy with venous vascular resection for pancreatic cancer: Impact of types of vein resection on timing and pattern of recurrence. Co-author DOI 10.1016/j.ejso.2023.03.229↗
  15. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  16. The impact of nutritional status on pancreatic cancer therapy. First author DOI 10.1080/14737140.2022.2026771↗
  17. Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies. Co-author DOI 10.3389/fonc.2021.812102↗
  18. Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer": What Is Good for the Surgeo… First author DOI 10.1097/sla.0000000000003655↗
  19. Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study. Co-author DOI 10.3389/fonc.2019.01299↗
  20. Preoperative sarcopenia determinants in pancreatic cancer patients. First author DOI 10.1016/j.clnu.2016.10.014↗
  21. Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery. Co-author DOI 10.1002/bjs.10063↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Massimo Falconi · 17 shared papers, 2019–2026 · strength 3.20
  2. Michele Reni · 12 shared papers, 2019–2026 · strength 2.25
  3. Diego Palumbo · 10 shared papers, 2022–2026 · strength 2.09
  4. Stefano Crippa · 11 shared papers, 2019–2026 · strength 2.07
  5. Stefano Partelli · 9 shared papers, 2019–2026 · strength 1.74
  6. Giulia Gasparini · 8 shared papers, 2023–2026 · strength 1.62
  7. Francesco DE COBELLI · 9 shared papers, 2016–2026 · strength 1.59
  8. Giulio Belfiori · 8 shared papers, 2019–2026 · strength 1.52
  9. Domenico Tamburrino · 8 shared papers, 2019–2026 · strength 1.52
  10. Marco Schiavo Lena · 6 shared papers, 2024–2026 · strength 1.27
  11. Federico De Stefano · 6 shared papers, 2023–2026 · strength 1.22
  12. Marina Macchini · 5 shared papers, 2022–2026 · strength 1.05
  13. Paolo Riccardo Camisa · 4 shared papers, 2024–2026 · strength 0.85
  14. Giovanni Guarneri · 4 shared papers, 2021–2026 · strength 0.81
  15. Giuseppe Malleo · 3 shared papers, 2026 · strength 0.68
  16. Gianpaolo Balzano · 5 shared papers, 2016–2026 · strength 0.65
  17. Roberto Salvia · 3 shared papers, 2023–2026 · strength 0.61
  18. Giulia Orsi · 3 shared papers, 2022–2026 · strength 0.60
  19. Gabriele Capurso · 3 shared papers, 2022–2026 · strength 0.57
  20. Catia Carconi · 2 shared papers, 2026 · strength 0.46
  21. Fabio Casciani · 2 shared papers, 2026 · strength 0.46
  22. Gabriella Lionetto · 2 shared papers, 2026 · strength 0.46
  23. Claudio Luchini · 2 shared papers, 2026 · strength 0.46
  24. Paolo Giorgio Arcidiacono · 2 shared papers, 2022–2024 · strength 0.34
  25. Claudio Fiorino · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.